Vaginal Cuff Brachytherapy Fractionation Study

Endometrial Cancer Clinical Trial

Official title:

A Randomized Phase III Trial of Two Standard Dose Fractionation Regimes for Adjuvant Vaginal Brachytherapy in Early Stage Endometrial Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03785288
• Other study ID #: 20163
• Status: Recruiting
• Phase: Phase 3
• Start date: January 17, 2019
• Est. completion date: January 1, 2026

Study information

• Verified date: May 2024
• Source: University of Virginia
• Contact: Song Wood
• Phone: 434-243-0008
• Email: UVARADONCClinicalTrials[@]uvahealth.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compare two standard of care treatments: HDR (high dose radiation) vaginal brachytherapy 3 fractions of 7 Gy to HDR vaginal brachytherapy 6 fractions of 4Gy for early stage endometrial cancer.

Description:

Patients are randomized to HDR vaginal brachytherapy 7 Gy in 3 fractions prescribed at 5mm. Radiation delivered 4-12 weeks after surgery OR HDR vaginal brachytherapy 4Gy in 6 fractions prescribed at the cylinder surface. Patients have the option to request to decline their randomization and switch to the alternate treatment ARM if they prefer.

Radiation delivered 4-12 weeks after surgery. Participants in all Arms will receive standard vaginal dilator for use after treatment (to promote healing). 3 month, 1 year and 2 year follow up assessments are performed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 258
• Est. completion date: January 1, 2026
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Willingness and ability to provide written informed consent and to comply with the study protocol as judged by the investigator.

• Surgery consisted of Total Abdominal or Laparoscopic Hysterectomy and Bilateral Salpingo Oophorectomy (TH-BSO) with or without lymph node dissection.

• Subject must have FIGO Stage I-II (grade 1-3) pathologically proven (histologic) endometrioid cancer, including all subtypes. Serous, clear cell, and carcinosarcoma histologic pathologies are allowed.

• Subjects must have no measurable disease after surgery.

• ECOG Performance Status of 0-2

• Age = 18 years

• Subject must have a life expectancy = 12 months

Exclusion Criteria:

• Disease of more advanced stage (FIGO stage III-IV) or disease for which adjuvant external beam radiation therapy or chemotherapy is indicated

• Patients with a history of prior pelvic radiation therapy or if additional pelvic radiation therapy is planned

• Subjects who have not recovered from side effects of agents administered more than 4 weeks prior to the on-study date

• Subjects that require > 14 weeks between surgery and initiation of radiation therapy on study unless the subject is receiving chemotherapy. Subjects receiving chemotherapy may have radiation therapy initiated within 6 months after surgery.

• Subjects who do not meet this criteria may still be eligible. The UVA Coordinating Center and Overall Study PI will review each case and inform the site of the approval decision.

• Subjects who are receiving any investigational agents or have had any investigational agent within the 30 days prior to the on-study date

• Subject is unable or unwilling to participate in a study-related procedure

• Pregnant and breastfeeding women are excluded from this study

• Subject is a prisoner

• A serious uncontrolled medical disorder that in the opinion of the Investigator would impair the ability of the subject to receive protocol therapy.

• Subjects with a history of evidence upon physical examination of central nervous system disease including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (stroke), transient ischemic attack, or subarachnoid hemorrhage within six months of study entry

Related Conditions & MeSH terms

• Endometrial Cancer
• Endometrial Neoplasms

Intervention

Radiation:
• HDR vaginal brachytherapy
HDR vaginal brachytherapy 7 Gy in 3 fractions or HDR vaginal brachytherapy 4 Gy in 6 fractions

Locations

Country	Name	City	State
United States	University of Maryland Medical Center (UMMC)	Baltimore	Maryland
United States	University of Virginia	Charlottesville	Virginia
United States	SUNY Upstate Medical University	Syracuse	New York

Sponsors (1)

Lead Sponsor	Collaborator
Kara Romano, MD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Female Sexual Function Index (FSFI)	Using the FSFI, compare patient reported sexual dysfunction at 1 year after completion of treatment	1 year
Primary	Preference Option Randomized Design (PORD)	Assessing the comparative effectiveness of receiving HDR vaginal brachytherapy on Arm B or Arm A for early stage endometrial cancer.	1 year
Secondary	Vaginal Length Measurement	Using vaginal dilator compare patient vaginal measurement 1 year after completion of treatment	1 year
Secondary	Vaginal Length Measurement	Using vaginal dilator compare patient vaginal measurement 2 years after completion of treatment	2 years